Dupixent (dupilumab) FDA approval for bullous pemphigoid: Jun 18, 2025
Page updated ·next FDA decision on the calendar·Data as of Nov 19, 2026 12:24 AM ET
✓ APPROVED
DUPIXENT (dupilumab) was approved by the FDA on June 18, 2025 for adults with bullous pemphigoid.
Verified against: FDA action day June 18, 2025 (BLA 761055 S-070 (FDA letter)) · Announcement June 20, 2025 · Goal date: none on record.
This page was first committed to pdufa.bio's public repository on Nov 17, 2026, 10:25 PM ET (public commit d939eae). Dates on this page are the FDA's and the sponsor's; this line is ours.
The FDA approved Dupixent (dupilumab) for adults with bullous pemphigoid on June 18, 2025, its eighth approved use in the US. Sanofi and Regeneron announced it on June 20.
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (12/24/24) through T+5. Run-up high $59.42 on 3/6/25, low $47.62 on 6/18/25 (T-120 to T-1). Announced 6/20/25 (FDA action 6/18/25). Historical price action, not a forecast.
Positioning before the decision
On May 19, 2025, 14 days before the decision date, at-the-money options priced a move of ±5.5% through Jun 20, 2025 (the first listed expiry after the decision; ATM implied volatility 23%). The stock closed -0.4% at the first close across the decision and +2.2% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Key facts
FDA decision date2025-06-18
Announced2025-06-20
OutcomeApproved
Drug / candidateDUPIXENT (dupilumab)
IndicationAdults with bullous pemphigoid
CompanySanofi
Market-cap tierLarge
120-day run-up (T-120→T-1)-1.6%
Decision-day move+0.5%
Move measured on2025-06-20 close (the announcement day), against the 2025-06-18 close
Cohort decision-day move (history)1.0% median (n=828)
The FDA's approval letter for supplement 70 to BLA 761055 is dated June 18, 2025 (FDA letter). Sanofi and Regeneron announced the approval on June 20, 2025 (Sanofi's release). This page replaces one dated June 2, 2025, a day nothing happened (see /corrections).
Run-up figures are the stock's own daily closing path over the 120 trading days before the decision, from our price history. Cohort move is the historical median absolute decision-day move for this market-cap tier. History, not a prediction.
FDA record of the action: the FDA approved on June 18, 2025, per BLA 761055 S-070 (FDA letter). The sponsor announced it on June 20, 2025. Action dates on pdufa.bio come from the FDA's own record, not the press release. Every FDA action we hold, by FDA date: FDA approval letters.
Questions
Was DUPIXENT (dupilumab) approved by the FDA?
Yes. The FDA approved the application for DUPIXENT (dupilumab) on June 18, 2025, per the FDA's own record. The company announced it on June 20, 2025. The primary source is linked on this page.
Which company is behind DUPIXENT (dupilumab)?
DUPIXENT (dupilumab) is a Sanofi (SNY) program. The FDA decision came on June 18, 2025; the company's own announcement is linked on this page.
How did SNY stock react to the FDA decision?
SNY moved +0.5%, measured as the 2025-06-20 close (the announcement day) against the 2025-06-18 close. It is one trading day's move, so it can include news other than the decision. Historical measurement, not a prediction, and not investment advice.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.
Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.